Navigation Links
Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Date:5/12/2011

SAN FRANCISCO, May 12, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that key data from its Phase 2 randomized clinical study in advanced liver cancer patients, along with data from other JX-594 clinical trials, will be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 18-21, 2011, in Seattle, Washington.  These data, evaluating multi-dose administration of JX-594 in U.S., Korean and Canadian patients with advanced liver cancer, were selected for an oral presentation at the ASGCT Presidential Symposium. Additionally, these data have been chosen for inclusion in ASGCT's Media Event to be held during the annual meeting.

The presentation details are as follows:

Abstract Title: "Demonstration of Safety and Antitumoral Activity of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, Following Intravenous Infusion and/or Intratumoral Injections in Patients with Refractory Metastatic Cancers" (Abstract #50)

Presenter: David H. Kirn, M.D., president and chief executive officer of Jennerex

Session: Presidential Symposium, May 19, 2011, 9:05 a.m. PDT

About JX-594

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or systemically, induces tumor shrinkage and/or necrosis
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
2. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
3. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
4. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
5. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Closes $5 Million First Tranche of Series C Financing
8. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
9. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
10. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
11. Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... N.J. , March 3, 2015  Thingee Corporation, ... will be delivering a presentation entitled, "Technology Adoption: Making ... Thriving through Innovations and Technology ,  in ... March 11 to 13, 2015. Audiences looking to learn ... effectively will want to be in the audience for ...
(Date:3/3/2015)... March 03, 2015 Genedata, a ... discovery and life science research, today announced that ... enterprise platform for use at Pfizer biopharma research ... Genedata is supporting Pfizer’s global deployment and roll ... Centers for Therapeutic Innovation (CTI), and Pharmaceutical Sciences ...
(Date:3/3/2015)... , March 3, 2015  Johnson & Johnson ... South San Francisco (JLABS @SSF), a ... South San Francisco, Calif. The ... up to 50 startups from across the healthcare spectrum ... The first resident startups have been ...
(Date:3/3/2015)... , March 3, 2015  PDL BioPharma, Inc. ... today announced that the third of three shareholder lawsuits ... without prejudice. On February 2, 2015, a ... September on behalf of a putative class of purchasers ... et al., No. 2:14-CV-01526-APG-NJK (D. Nev.), was voluntarily dismissed ...
Breaking Biology Technology:Thingee to present at 11th Annual Synergistix Users Conference 2Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit 2
... a way to wake up the immune system to ... a nanoscale container called a vault directly into lung ... disease growth. The vaults, barrel-shaped nanoscale capsules found ... to slowly release a protein, the chemokine CCL21, into ...
... physical therapists are delighted the members of the California ... importance of Senate Bill 924 and its value to ... Physical Therapy Association, will improve the health care process ... delays and unnecessary costs because they have been unable ...
... Calif., May 3, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... and CEO, will provide an update on the progress of ... company,s business strategy at two investor conferences in the month ... Lynch Health Care Conference at 10:40 am PT (1:40 pm ...
Cached Biology Technology:UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs 2UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs 3UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs 4Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences 2
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... Boston, MA Tuesday, March 3, 2015 at 11.20 ... Orlando, FL Wednesday, March 4, 2015 ... To access the live webcasts for these events, please visit ...
(Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... Feb. 5, 2015  Marken is starting its 35 ... has launched a new marketing campaign to solidify its ... The new campaign focuses on First as ... shipments. The first headline in the series, ... priorities with its client,s priorities. Marken recognizes the need ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... dangers to human health and the environment. North Carolina ... from the U.S. Environmental Protection Agency (EPA) that targets ... overflows every year, and will give urban planners new ... At issue are overflows from "sanitary" sewer systems, ...
... scientists have inventoried an astonishing abundance, diversity and distribution of ... that somehow manage a living in a frigid black world ... Revealed via deep-towed cameras, sonar and other vanguard ... now number 17,650, a diverse collection of species ranging from ...
... b3c newswire / - KINAXO Biotechnologies GmbH ... two new investors in the company, Leifina and Conmit ... Schumacher has been elected as a new member of ... Ullrich, Hellmut Kirchner, Manfred Ferber as well as the ...
Cached Biology News:Lose the fat: Targeting grease to curtail sewer overflows 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 3Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 4Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 5Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 6Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 7Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 8Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 9KINAXO Completes Financing Round to Enhance Biomarker Development 2KINAXO Completes Financing Round to Enhance Biomarker Development 3
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
... Protein Kit is a simple and convenient method ... The kit has been optimized for use with ... used for any fungus species that is susceptible ... procedure effectively generates spheroplasts of yeast cells that ...
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
Biology Products: